Article

Personalizing Atomoxetine Dosing in Children with ADHD: What Can We Learn from Current Supporting Evidence

2022-07-13

Abstract excerpt

Atomoxetine is the first non-stimulant medication approved by the US Food and Drug Administration for the treatment of attention deficit/hyperactivity disorder (ADHD). It can significantly improve ADHD symptoms, with good efficacy and tolerability. However, its efficacy was not consistent among all patients, especially for pediatric population. Due to marked heterogeneity in treatment response, a precision therapy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 74d477fa-0aa8-56f2-9fb1-da18eceba8b7
DOI: 10.22541/au.165771198.87924835/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Personalizing Atomoxetine Dosing in Children with ADHD: What Can We Learn from Current Supporting EvidenceDOI 10.22541/au.165771198.87924835/v1Read

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.Semantic proximity Read

ADHD pharmacogenetics across the life cycle: New findings and perspectivesSemantic proximity Read

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.Semantic proximity Read

Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.Semantic proximity Read

Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp><i>2D6</i> Genotype and Atomoxetine TherapySemantic proximity Read

Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD.Semantic proximity Read

Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.Semantic proximity Read

Pharmacogenetic Approach for a Better Drug Treatment in ChildrenSemantic proximity Read

Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.Semantic proximity Read

Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.Semantic proximity Read

Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen.Semantic proximity Read

Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.Semantic proximity Read